DE60045082D1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents
Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutyninInfo
- Publication number
- DE60045082D1 DE60045082D1 DE60045082T DE60045082T DE60045082D1 DE 60045082 D1 DE60045082 D1 DE 60045082D1 DE 60045082 T DE60045082 T DE 60045082T DE 60045082 T DE60045082 T DE 60045082T DE 60045082 D1 DE60045082 D1 DE 60045082D1
- Authority
- DE
- Germany
- Prior art keywords
- oxybutynin
- desethyloxybutynin
- smooth muscle
- optically pure
- musculatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XIQVNETUBQGFHX-QFIPXVFZSA-N (R)-oxybutynin Chemical compound C1([C@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-QFIPXVFZSA-N 0.000 title 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 title 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 3
- SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 abstract 3
- 208000013403 hyperactivity Diseases 0.000 abstract 3
- 229960005434 oxybutynin Drugs 0.000 abstract 3
- 210000002460 smooth muscle Anatomy 0.000 abstract 3
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/015515 WO2001093683A1 (en) | 2000-06-07 | 2000-06-07 | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60045082D1 true DE60045082D1 (de) | 2010-11-18 |
Family
ID=21741461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60045082T Expired - Lifetime DE60045082D1 (de) | 2000-06-07 | 2000-06-07 | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1286591B1 (enExample) |
| JP (1) | JP5684964B2 (enExample) |
| CN (3) | CN101108176A (enExample) |
| AT (1) | ATE483459T1 (enExample) |
| AU (2) | AU2000255966B2 (enExample) |
| CA (1) | CA2378754A1 (enExample) |
| DE (1) | DE60045082D1 (enExample) |
| ES (1) | ES2350330T3 (enExample) |
| WO (1) | WO2001093683A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002241721A1 (en) * | 2001-12-21 | 2003-09-02 | Bridge Pharma, Inc. | A non-arrhythmogenic metabolite of oxybutynin |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| EP1629850B2 (en) * | 2004-08-24 | 2013-05-22 | N.V. Nutricia | Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides |
| US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
| CN110152000A (zh) | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| EP2714011B1 (en) | 2011-06-03 | 2018-01-31 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
| US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
| US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
| US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
| US20160151321A1 (en) | 2012-11-13 | 2016-06-02 | Dinesh C. Patel | Methods for the treatment of sialorrhea |
| US20140135392A1 (en) * | 2012-11-13 | 2014-05-15 | NeuRx Pharmaceuticals LLC | Methods for the treatment of sialorrhea |
| CN103169660B (zh) * | 2013-04-15 | 2015-04-08 | 石正国 | 一种制备高包封率的利巴韦林脂质体口服乳 |
| WO2015095576A1 (en) | 2013-12-18 | 2015-06-25 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
| EP3151837B1 (en) | 2014-06-03 | 2023-03-15 | Signpath Pharma, Inc. | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies |
| ES3014023T3 (en) | 2016-04-27 | 2025-04-16 | Signpath Pharma Inc | Prevention of drug-induced atrio-ventricular block |
| IL297877A (en) | 2020-05-05 | 2023-01-01 | Apnimed Inc Delaware | Polymorphic forms of (r)-oxybutynin hydrochloride |
| IL299572A (en) * | 2020-07-03 | 2023-02-01 | Phoxbio Ltd | Reduction of viral infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008269A (en) * | 1970-05-05 | 1977-02-15 | William H. Rorer, Inc. | Phenylacetic acids |
| IT1231237B (it) * | 1987-09-21 | 1991-11-26 | Angeli Inst Spa | Derivati eterociclici |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| US5973182A (en) * | 1998-10-22 | 1999-10-26 | Sepracor Inc. | Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters |
-
2000
- 2000-06-07 DE DE60045082T patent/DE60045082D1/de not_active Expired - Lifetime
- 2000-06-07 EP EP00941235A patent/EP1286591B1/en not_active Expired - Lifetime
- 2000-06-07 CN CNA2007101418683A patent/CN101108176A/zh active Pending
- 2000-06-07 AU AU2000255966A patent/AU2000255966B2/en not_active Expired
- 2000-06-07 WO PCT/US2000/015515 patent/WO2001093683A1/en not_active Ceased
- 2000-06-07 JP JP2002501260A patent/JP5684964B2/ja not_active Expired - Fee Related
- 2000-06-07 ES ES00941235T patent/ES2350330T3/es not_active Expired - Lifetime
- 2000-06-07 AT AT00941235T patent/ATE483459T1/de not_active IP Right Cessation
- 2000-06-07 AU AU5596600A patent/AU5596600A/xx active Pending
- 2000-06-07 CN CN00819623A patent/CN1454054A/zh active Pending
- 2000-06-07 CA CA002378754A patent/CA2378754A1/en not_active Abandoned
-
2003
- 2003-05-16 CN CN03131438A patent/CN1451388A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2350330T3 (es) | 2011-01-21 |
| CA2378754A1 (en) | 2001-12-13 |
| AU2000255966B2 (en) | 2005-03-24 |
| CN101108176A (zh) | 2008-01-23 |
| AU5596600A (en) | 2001-12-17 |
| EP1286591B1 (en) | 2010-10-06 |
| CN1454054A (zh) | 2003-11-05 |
| AU2000255966A1 (en) | 2002-03-07 |
| JP2003535110A (ja) | 2003-11-25 |
| EP1286591A1 (en) | 2003-03-05 |
| WO2001093683A1 (en) | 2001-12-13 |
| CN1451388A (zh) | 2003-10-29 |
| EP1286591A4 (en) | 2007-04-04 |
| JP5684964B2 (ja) | 2015-03-18 |
| ATE483459T1 (de) | 2010-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60045082D1 (de) | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin | |
| ATE292971T1 (de) | (s,s)-reboxetin zur behandlung von peripheren neuropathien | |
| CA2451474A1 (en) | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion | |
| DE60027769D1 (de) | Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase | |
| DK1202736T3 (da) | Nikotin i terapeutisk angiogenese og vasculogenese | |
| AU2001283963A1 (en) | Polysiloxane polymers, method for their production and the use thereof | |
| EA200700116A1 (ru) | Четвертичные соли, антагонисты ccr2 | |
| WO2002103103A3 (en) | Fluorine-containing compounds and polymers derived therefrom | |
| WO2004006853A3 (en) | Treatment and prophylaxis with 4-1bb-binding agents | |
| NO20054296D0 (no) | Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep | |
| DK0786991T3 (da) | Polyaminforbindelsre til behandling af proliferative karsygdomme | |
| NO20041166L (no) | Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament | |
| DE60014136D1 (de) | Sapogenin derivate zur behandlung von kognitiven störungen | |
| CY1106409T1 (el) | Παραγωγα κινολινης | |
| WO2006050045A3 (en) | Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases | |
| NO976112L (no) | 1,6-disubstituerte isokromaner for behandling av migrene | |
| FR2872508B1 (fr) | Composition de traitement d'un verre pour en ameliorer la resistance mecanique par guerison des defauts de surface, procedes de traitement correspondants et verres traites obtenus | |
| WO2003092611A3 (en) | Methods of inducing formation of functional and organized lymphatic vessels | |
| DK1368023T3 (da) | Anvendelse af buprenoprphin til behandling af urininkontinens | |
| EP1152760A4 (en) | USE OF 4-AMINOPYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | |
| NO20042138L (no) | Forbindelser og fremgangsmate for behandling av hyperaktiv blaere | |
| YU22802A (sh) | Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina | |
| DK1744736T3 (da) | Fremgangsmåde til behandling af problemer med tørre øjne og uveitis | |
| EP1233075A3 (en) | BDNF polymorphism and association with bipolar disorder | |
| MXPA04004980A (es) | Antagonistas del receptor ccr-3. |